 2005 |
|
 November 29 |
AnGes Group Forms Business Alliance with FALCO biosystems |
| November 22 |
Completion of Trial Subject Enrollment for U.S. Phase I Clinical Trial of HGF Plasmid for Ischemic Heart Disease (IHD) |
| October 11 |
Osaka University, AOKI and AnGes MG Joint Development Project Launched
- Development of Fully Bioabsorbable Next-generation Magnesium Stent - |
| October 4 |
Medical -Use Patent for HGF (VEGF) Gene Granted in the U.S.
− Covering Cerebrovascular Disorders − |
| October 3 |
Hosokawa Powder Technology Research Institute
Succeeds in Encapsulating Nucleic Acid Drug Developed by AnGes MG
within Drug Delivery System (DDS) Nanoparticles
− Evaluation of “Nucleic Acid DDS Preparation” Technology
for Inflammatory Dermatoses Begins − |
| September 26 |
Domestic Clinical Trial for NFκB Decoy Oligo Launched
− Phase I Clinical Trial in Atopic Dermatitis Commences − |
| August 15 |
Basic Patent for HVJ-E Is Granted in the U.S. Covering HVJ-E As a Foreign Gene Transferring Vector
(Patent for material, usage/transfection method and preparation process of HVJ-E) |
| August 10 |
Avontec (Germany) and AnGes MG to form an Alliance
-- Obtained a license of STAT-1 Decoy Oligo in Asi -- |
| August 10 |
Nikko Principal Investments Japan Ltd and AnGes MG Inc to form an alliance in Pharma/Lifesciences area
~ An Alliance Fund has been jointly established, and the first investment just completed to a drug development company ~ |
| July 25 |
Pharmaceuticals and Medical Devices Agency Completes Review of
Initial IND for NFκB Decoy Oligo
-
Phase I Clinical Trial in Atopic Dermatitis Underway
- |
| July 8 |
AnGes MG Forms Business Alliance with Alfresa Pharma Corporation
-
Joint Research on Atopic Dermatitis Therapeutic Medicine to Prepare
for AnGes MG Establishing its own Sales Network
- |
| June 21 |
Rush University Medical Center /USA and AnGes MG executes License Agreement
- AnGes obtains the exclusive right to develop and sell NFκB Decoy Oligonucleotide as a treatment for Disc Degeneration - |
| June 13 |
Basic patent of HGF gene therapy is granted in Europe
- Our foundation of HGF gene therapy international development is strengthened. - |
| June 8 |
AnGes MG Starts to Explore Feasibility of a New DDS Drug with MedGel
- Toward Expanding the Application Range of NFκB Decoy Oligo - |
| May 24 |
Execution of License Agreement with Vical (USA) related to Non-viral Gene Delivery Technology
--Obtained an exclusive right for HGF gene’s delivery-- |
| April 28 |
GenomIdea Launches Service with Mitsubishi Space Software
- Drug Design Service for Next-Generation Nucleic Acid Medicine “siRNA” - |
| April 27 |
Completion of Trial Subject Enrollment for the US Phase II Clinical Trial of HGF Plasmid for Peripheral Arterial Disease (PAD) |
| January 26 |
Launch of Joint Research Project between the University of Tokyo Hospital and AnGes MG
--To develop cutting-edge clinical medicine, including genetic medication and cell remediation medicines-- |
| January 24 |
The Research-and-Development Type Venture Business Consortium That Includes AnGes MG, To Receive Research Grant From New Energy and Industrial Technology Development Organization
--Development of NFκB decoy oligo therapeutic agent for IBD-- |
 |
|
| 2004 |
|
| December 9 |
AnGes MG Selected by Pharmaceuticals and Medical Devices Agency for Research Grant
--Clinical trials are anticipated using NFκB decoy oligo therapeutic agent for atopic dermatitis-- |
| November 24 |
Phase I clinical trials of HGF plasmid for the treatment of Ischemic Heart Disease (IHD) underway in the United States
-- Clinical trials of HGF plasmid for both peripheral arterial disease (PAD) and IHD -- |
| November 9 |
AnGes MG Joins Hands with ImmunoFrontier
-- Transfer of Patent Rights for Cancer DNA Vaccine -- |
| September 1 |
Announcement: Relocation of Headquarters and Research Center
-- Integration of Headquarters and Research Center to Saito -- |
| July 26 |
GenomIdea's Joint Development with Mitsubishi Space Software Bears Fruit
-- Development of a New Drug Design System for the Next-generation Nucleic acid Medicine "siRNA" Completed -- |
| July 12 |
The U.S. Food and Drug Administration (FDA) has given the go-ahead for a clinical trial investigating AnGes' HGF plasmid for the treatment of ischemic heart disease (IHD). This U.S. study will be the first clinical investigation of HGF plasmid for IHD. |
| June 30 |
AnGes MG to Join the University of Tokyo (Hospital) Project:"22nd Century Medical Center" (tentative name)
-Establishes joint research program on forefront clinical medicine, including development of genetic medication and cell remediation medicines.- |
| June 28 |
Launch of Shimadzu Corporation and AnGes MG Joint Research Project
-To develop a new therapy for refractory dermatosis with nucleic acid medicines administered via the needleless pressure injector "Shima JET." - |
| June 7 |
AnGes MG Forms a Business Alliance with NeoChemir.
Expands treatments of ischemic diseases through introduction of a new carbon dioxide generating wound dressing material |
| March 23 |
AnGes MG Seeks Faster New Drug Approval-Applications Via Document Management System
-Infocom to be systems integrator for application submission system- |
| March 17 |
AnGes MG Expanding Its US Presence
-Licensing activities now in full-swing on the bioventure-rich US West Coast- |
| March 17 |
Commencement of Clinical trials for HGF Genetic Medicine in Japan
-The first multi-centered double-blind trial for genetic medicine in Japan- |
| February 26 |
Investigational New Drug (IND) application filedwith the USFDA for HGF genetic medicine against ischemic heart disease
- Peripheral arterial disease and ischemic heart disease related clinical trials in the USA - |
| February 20 |
AnGes MG appoints new director |
| February 2 |
AnGes MG and Gene Design Inc. embark on joint development
of next-generation decoy nucleotides as part of their
push into the field of systemic diseases including cancer and IBD |
|
|
| 2003 |
|
| December 8 |
Japanese medical-use patent issued for NF B decoy oligo
-Covering treatment and preventive drugs for ischemic diseases, organ transplantions and cancers - |
| December 2 |
AnGes MG receives green light from the Japanese Ministry of Health for its clinical trials for HGF genetic medicine
-Japan's first large-scale multi-centered double-blind clinical trials for genetic medicine underway - |
| October 14 |
AnGes MG and Hokkaido System Science Co., Ltd. establish corporate alliance
-Granting of manufacture and marketing rights for NFB decoy oligo reagent- |
| August 4 |
AnGes MG and Gene Design Inc. establish joint operations
- Granting manufacturing and marketing rights for a novel nucleic acid sequence - |
| July 28 |
Key Japanese patent issued covering HGF gene therapy |
| June 23 |
AnGes MG transfers part of HVJ-E operations to subsidiary |
| May 15 |
AnGes MG, Inc. and Goodman Co., Ltd. Execute Exclusive License |
| May 1 |
Clinical trials underway for HGF genetic medicine in the United States |
| March 24 |
Notification of joint genetic function analysis R&D |
| February 20 |
Notice on the Granting of Stock Options |
| February 20 |
Personnel Changes at AnGes MG |
| February 10 |
Key Personnel Change at AnGes MG |
| January 8 |
IND application approved for HGF genetic medicine
treating peripheral arterial diseases |
|
|
